A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Tomescu, Costin ^a   Liu, Qin ^a   Ross, Brian N ^a   Yin, Xiangfan ^a   Lynn, Kenneth ^b   Mounzer, Karam C ^c   Kostman, Jay R ^b   Montaner, Luis J ^a  

^a WISTAR INSTITUTE   (United States)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^c Philadelphia Fight   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; GAG PROTEIN; GAMMA INTERFERON; POL PROTEIN; VIRUS RNA;

ADAPTIVE IMMUNITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRANULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INNATE IMMUNITY; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; PLASMACYTOID DENDRITIC CELL; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS LOAD; BLOOD; COMPARATIVE STUDY; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION;

ADAPTIVE IMMUNITY; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; MULTIVARIATE ANALYSIS; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 84905365070     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103209     Document Type: Article

References (71)

1. Autran B, Descours B, Avettand-Fenoel V, Rouzioux C (2011) Elite controllers as a model of functional cure. Curr Opin HIV AIDS 6: 181-187.
2. Deeks SG, Walker BD (2007) Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral Therapy. Immunity 27: 1-11.
3. Huff B (2005) Who are the elite controllers? GMHC Treat Issues 19: 12.
4. Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, et al. (2005) HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 41: 1053-1056. (Pubitemid 41368233)
5. Saez-Cirion A, Pancino G, Sinet M, Venet A, Lambotte O (2007) HIV controllers: how do they tame the virus? Trends Immunol 28: 532-540.
6. Walker BD (2007) Elite control of HIV Infection: implications for vaccines and treatment. Top HIV Med 15: 134-136.
7. Buzon MJ, Seiss K, Weiss R, Brass AL, Rosenberg ES, et al. (2011) Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers. J Virol 85: 9646-9650.
8. Chen H, Li C, Huang J, Cung T, Seiss K, et al. (2011) CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 121: 1549-1560.
9. Hersperger AR, Martin JN, Shin LY, Sheth PM, Kovacs CM, et al. (2012) Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood 117: 3799-3808.
10. Machmach K, Leal M, Gras C, Viciana P, Genebat M, et al. (2012) Plasmacytoid Dendritic Cells Reduce HIV Production in Elite Controllers. J Virol 86: 4345-4252.
11. O'Connell KA, Han Y, Williams TM, Siliciano RF, Blankson JN (2009) Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. J Virol 83: 5028-5034.
12. Owen RE, Heitman JW, Hirschkorn DF, Lanteri MC, Biswas HH, et al. (2010) HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS 24: 1095-1105.
13. Pereyra F, Palmer S, Miura T, Block BL, Wiegand A, et al. (2009) Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis 200: 984-990.
14. Costello C, Tang J, Rivers C, Karita E, Meizen-Derr J, et al. (1999) HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women. Aids 13: 1990-1991. (Pubitemid 29509568)
15. McNeil AJ, Yap PL, Gore SM, Brettle RP, McColl M, et al. (1996) Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. Qjm 89: 177-185. (Pubitemid 26086136)
16. den Uyl D, van der Horst-Bruinsma IE, van Agtmael M (2004) Progression of HIV to AIDS: a protective role for HLA-B27? AIDS Rev 6: 89-96. (Pubitemid 39149447)
17. Migueles SA, Laborico AC, Imamichi H, Shupert WL, Royce C, et al. (2003) The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences. J Virol 77: 6889-6898. (Pubitemid 36666882)
18. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, et al. (2008) HLA Class I-Restricted T Cell Responses May Contribute to the Control of HIV Infection, but Such Responses are Not Always Necessary for Long-term Virus Control. J Virol 207: 61-75.
19. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, et al. (2008) Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 197: 563-571. (Pubitemid 351321534)
20. Bailey JR, Williams TM, Siliciano RF, Blankson JN (2006) Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med 203: 1357-1369. (Pubitemid 43736603)
21. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A (2002) Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 169: 6376-6385. (Pubitemid 36903486)
22. Julg B, Williams KL, Reddy S, Bishop K, Qi Y, et al. (2010) Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J Virol 84: 5540-5549.
23. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, et al. (2006) Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 80: 3617-3623.
24. Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, et al. (2009) HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J Virol 83: 2743-2755.
25. Mothe B, Llano A, Ibarrondo J, Zamarreno J, Schiaulini M, et al. (2012) CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One 7: e29717.
26. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13: 46-53. (Pubitemid 46067385)
27. Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, et al. (2011) Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med 9: 208.
28. Rolland M, Heckerman D, Deng W, Rousseau CM, Coovadia H, et al. (2008) Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One 3: e1424.
29. Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, et al. (2007) Gagspecific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 178: 2746-2754. (Pubitemid 46333151)
30. Brumme ZL, Li C, Miura T, Sela J, Rosato PC, et al. (2011) Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers. J Acquir Immune Defic Syndr 56: 100-108.
31. Granier C, Battivelli E, Lecuroux C, Venet A, Lambotte O, et al. (2013) Pressure from TRIM5alpha contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles. J Virol 87: 10368-10380.
32. Miura T, Brockman MA, Brumme ZL, Brumme CJ, Pereyra F, et al. (2009) HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J Virol 83: 140-149.
33. Miura T, Brumme CJ, Brockman MA, Brumme ZL, Pereyra F, et al. (2009) HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J Virol 83: 3407-3412.
34. Lopez-Vazquez A, Mina-Blanco A, Martinez-Borra J, Njobvu PD, Suarez-Alvarez B, et al. (2005) Interaction between KIR3DL1 and HLA-B*57 supertype alleles influences the progression of HIV-1 infection in a Zambian population. Hum Immunol 66: 285-289. (Pubitemid 40395248)
35. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, et al. (2002) Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31: 429-434. (Pubitemid 35154456)
36. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, et al. (2007) Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 39: 733-740. (Pubitemid 46848586)
37. Long BR, Ndhlovu LC, Oksenberg JR, Lanier LL, Hecht FM, et al. (2008) KIR3DS1 Conferral of Enhanced Natural Killer Cell Function in Early HIV-1 Infection. J Virol 82: 4785-4792. (Pubitemid 351657040)
38. Boulet S, Song R, Kamya P, Bruneau J, Shoukry NH, et al. (2010) HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells. J Immunol 184: 2057-2064.
39. Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, et al. (2011) Receptor-Ligand Requirements for Increased NK Cell Polyfunctional Potential in Slow Progressors Infected with HIV-1 Coexpressing KIR3DL1*h/*y and HLA-B*57. J Virol 85: 5949-5960.
40. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, et al. (2007) Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 204: 3027-3036. (Pubitemid 350179568)
41. Vieillard V, Fausther-Bovendo H, Samri A, Debre P (2010) Specific phenotypic and functional features of natural killer cells from HIV-infected long-term nonprogressors and HIV controllers. J Acquir Immune Defic Syndr 53: 564-573.
42. Tomescu C, Duh FM, Hoh R, Viviani A, Harvill K, et al. (2012) Impact of Protective KIR/HLA Genotypes on NK Cell and T Cell Function in HIV-1 Infected Controllers. AIDS 26: 1869-1878.
43. Freeman CM, Martinez FJ, Han MK, Ames TM, Chensue SW, et al. (2009) Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med 180: 1179-1188.
44. Tomescu C, Duh FM, Lanier MA, Kapalko A, Mounzer KC, et al. (2010) Increased plasmacytoid dendritic cell maturation and natural killer cell activation in HIV-1 exposed, uninfected intravenous drug users. AIDS 24: 2151-2160.
45. De Maria A, Fogli M, Costa P, Murdaca G, Puppo F, et al. (2003) The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol 33: 2410-2418. (Pubitemid 37138973)
46. Mavilio D, Benjamin J, Daucher M, Lombardo G, Kottilil S, et al. (2003) Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A 100: 15011-15016. (Pubitemid 37518008)
47. Sirianni MC, Mezzaroma I, Aiuti F, Moretta A (1994) Analysis of the cytolytic activity mediated by natural killer cells from acquired immunodeficiency syndrome patients in response to phytohemagglutinin or anti-CD16 monoclonal antibody. Eur J Immunol 24: 1874-1878. (Pubitemid 24237561)
48. Alter G, Malenfant JM, Delabre RM, Burgett NC, Yu XG, et al. (2004) Increased natural killer cell activity in viremic HIV-1 infection. J Immunol 173: 5305-5311. (Pubitemid 39387815)
49. Alter G, Teigen N, Ahern R, Streeck H, Meier A, et al. (2007) Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis 195: 1452-1460. (Pubitemid 46717463)
50. Eller MA, Eller LA, Ouma BJ, Thelian D, Gonzalez VD, et al. (2009) Elevated natural killer cell activity despite altered functional and phenotypic profile in Ugandans with HIV-1 clade A or clade D infection. J Acquir Immune Defic Syndr 51: 380-389.
51. Tomescu C, Chehimi J, Maino VC, Montaner LJ (2009) Retention of viability, cytotoxicity, and response to IL-2, IL-15, or IFN-{alpha} by human NK cells after CD107a degranulation. J Leukoc Biol 85: 871-876.
52. Payne RP, Kloverpris H, Sacha JB, Brumme Z, Brumme C, et al. (2010) Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells. J Virol 84: 10543-10557.
53. Dave B, Kaplan J, Gautam S, Bhargava P (2012) Plasmacytoid dendritic cells in lymph nodes of patients with human immunodeficiency virus. Appl Immunohistochem Mol Morphol 20: 566-572.
54. Lehmann C, Jung N, Forster K, Koch N, Leifeld L, et al. (2014) Longitudinal analysis of distribution and function of plasmacytoid dendritic cells in peripheral blood and gut mucosa of HIV infected patients. J Infect Dis 209: 940-949.
55. Malleret B, Maneglier B, Karlsson I, Lebon P, Nascimbeni M, et al. (2008) Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood 112: 4598-4608.
56. Reeves RK, Evans TI, Gillis J, Wong FE, Kang G, et al. (2012) SIV infection induces accumulation of plasmacytoid dendritic cells in the gut mucosa. J Infect Dis 206: 1462-1468.
57. Brown KN, Trichel A, Barratt-Boyes SM (2007) Parallel loss of myeloid and plasmacytoid dendritic cells from blood and lymphoid tissue in simian AIDS. J Immunol 178: 6958-6967. (Pubitemid 46847422)
58. Brown KN, Wijewardana V, Liu X, Barratt-Boyes SM (2009) Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection. PLoS Pathog 5: e1000413.
59. Feldman M, Howell D, Fitzgerald-Bocarsly P (1992) Interferon-alpha- dependent and -independent participation of accessory cells in natural killer cell-mediated lysis of HSV-1-infected fibroblasts. J Leukoc Biol 52: 473-482.
60. Fitzgerald-Bocarsly P, Feldman M, Curl S, Schnell J, Denny T (1989) Positively selected Leu-11a (CD16+) cells require the presence of accessory cells or factors for the lysis of herpes simplex virus-infected fibroblasts but not herpes simplex virus-infected Raji. J Immunol 143: 1318-1326. (Pubitemid 19211367)
61. Bandyopadhyay S, Perussia B, Trinchieri G, Miller DS, Starr SE (1986) Requirement for HLA-DR + accessory cells in natural killing of cytomegalovirusinfected fibroblasts. Journal of Experimental Medicine 164: 180-195. (Pubitemid 16069231)
62. Oh SH, Bandyopadhyay S, Miller DS, Starr SE (1987) Cooperation between CD16(Leu-11b)+ NK cells and HLA-DR+ cells in natural killing of herpesvirus-infected fibroblasts. J Immunol 139: 2799-2802. (Pubitemid 17153963)
63. Perussia B, Fanning V, Trinchieri G (1985) A leukocyte subset bearing HLA-DR antigens is responsible for in vitro alpha interferon production in response to viruses. Nat Immun Cell Growth Regul 4: 120-137. (Pubitemid 15228688)
64. Tomescu C, Chehimi J, Maino VC, Montaner LJ (2007) NK Cell Lysis of HIV-1-Infected Autologous CD4 Primary T Cells: Requirement for IFN-Mediated NK Activation by Plasmacytoid Dendritic Cells. J Immunol 179: 2097-2104.
65. Portales P, Reynes J, Pinet V, Rouzier-Panis R, Baillat V, et al. (2003) Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo. Aids 17: 495-504. (Pubitemid 36293102)
66. Portales P, Reynes J, Rouzier-Panis R, Baillat V, Clot J, et al. (2003) Perforin expression in T cells and virological response to PEG-interferon alpha2b in HIV-1 infection. AIDS 17: 505-511. (Pubitemid 36293103)
67. Papasavvas E, Chehimi J, Azzoni L, Pistilli M, Thiel B, et al. (2010) Retention of functional DC-NK cross-talk following up to 18 weeks therapy interruptions in chronically suppressed HIV type 1+ subjects. AIDS Res Hum Retroviruses 26: 1047-1049.
68. Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, et al. (2004) Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 1: e64.
69. Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, et al. (2013) Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 207: 213-222.
70. Hatzakis A, Gargalianos P, Kiosses V, Lazanas M, Sypsa V, et al. (2001) Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication. J Interferon Cytokine Res 21: 861-869. (Pubitemid 33078525)
71. Landau A, Batisse D, Piketty C, Kazatchkine MD (2000) Effect of interferon and ribavirin on HIV viral load. AIDS 14: 96-97. (Pubitemid 30072087)